Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

Crucell « Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

785 Posts, Pagina: « 1 2 3 4 5 6 ... 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 » | Laatste

Omlaag ↓

[verwijderd] 12 april 2010 12:12

gezien de PPS reactie , denkt de markt , er ongeveer hetzelfde over als ondergetekende.

Vaccin tegen baggeritis gevraagd!!!!!

Elk aandeel is beter dan C

14.70 , here we come again!: If not today, then tomorrow, or wednesday, thursday, friday.

Name a day and the 14.70 , will be there

maxen 12 april 2010 13:32

quote:
wilb52 schreef:
...
Elk aandeel is beter dan C
...

Dat is nou het leuke van die aandelen. Er schijnt een vrijheid van keuze in aanschaf ervan te bestaan. En als je eenmaal een aandeel hebt, en je bedenkt je, schijn je ze ook weer te kunnen verkopen. En dan kun je er elk ander aandeel voor terugkopen. Gezien bovenstaande quote hoef je in zo'n geval nauwelijks na te denken over een alternatief aandeel.

Slechts een tip!

patient 12 april 2010 16:19

quote:
wilb52 schreef:
gezien de PPS reactie , denkt de markt , er ongeveer hetzelfde over als ondergetekende.

Vaccin tegen baggeritis gevraagd!!!!!

Elk aandeel is beter dan C

14.70 , here we come again!: If not today, then tomorrow, or wednesday, thursday, friday.

Name a day and the 14.70 , will be there

Wilbert heeft net als ik ook een koopordertje op E14,70 ;Q)

[verwijderd] 12 april 2010 16:37

En op 14.50
14.10 en 13.75

de tuinman 12 april 2010 17:49

quote:
wilb52 schreef:
En op 14.50
14.10 en 13.75

Als je zoveel kooporders hebt staan dan heb je wel hele hoge verwachtingen van Crucell!!!!!!

[verwijderd] 12 april 2010 17:55

lage verwachtingen bedoel je (:->D)

de tuinman 12 april 2010 22:01

quote:
wilb52 schreef:
lage verwachtingen bedoel je (:->D)

Als je lage verwachtingen heb, waarom dan nog bijkopen?

flosz 22 april 2010 15:00

Interview met Sanofi’s Thomas Kelly, Shanghai Daily.
Embracing Chinese partnerships key
Q: How do you view the pharmaceutical industry in China?

A: I believe consolidation will be very important and significant in the next five years, driven by market forces and increased quality standards required by regulatory authorities. There are over 3,000 local pharmaceutical companies and around 60 vaccine companies. The market remains extremely fragmented compared with other parts of the world. Through this process of mergers and acquisitions, there will be tremendous opportunities for establishing new partnerships.

Q: How do you choose your partners?

A: We're currently in talks with different companies in different regions and provinces in an effort to find new partners.

Read more: www.shanghaidaily.com/article/?id=434...
********

Crucell and sanofi pasteur signed an exclusive collaboration and commercialization agreement for the development of a rabies monoclonal antibody combination using Crucell's PER.C6® manufacturing technology. This antibody cocktail is to be used with the rabies vaccine for post-exposure prophylaxis against this fatal disease.

Due to promising Phase I results of a US and an Indian study completed in 2007, Crucell was notified by the FDA Department of Health and Human Services that its rabies monoclonal antibody combination has been granted a Fast Track designation. Under the terms of the agreement, Crucell will continue to perform the development activities. Crucell will be responsible for the manufacturing of the final product and will retain exclusive distribution rights in Europe, co-exclusive distribution rights in China and the rights to sell to supranational organizations such as UNICEF.

www.crucell.cn/

China rabies vaccine recall prompts changes
Friday, April 2, 2010
More than 200,000 units of the rabies vaccines manufactured by Jiangsu Ealong Biotech Co. and Hebei Bioforwell Co. were recalled because they did not meet national quality standards, the administration said on its website.
It did not say what was wrong with the vaccine, or what symptoms people may have who took it. Rabies outbreaks are common in China, with more than 2,000 people dying annually in recent years after being bitten by infected dogs.
Jiangsu Ealong Biotech Co. issued a statement earlier this week saying it had stopped making the vaccine late last year after quality problems surfaced. The administration said Hebei Bioforwell also stopped production last year.
Requests for further information from the administration were not answered late Friday.
China's pharmaceutical industry is lucrative but often poorly regulated. Local manufacturers and other players in the drug supply chain have been blamed in recent years for deaths linked to counterfeit or shoddy medications at home and abroad.
www.cbc.ca/health/story/2010/04/02/ch...

[verwijderd] 27 april 2010 15:06

Onderstaande lijkt mij voor Sanofi een mogelijke reden om niet te hard met de ontwikkeling van een `cell based influenza vaccin"

Oppositions against patents of competitors

In 2005, we filed opposition against a European patent held by Novartis Vaccines and Diagnostics (formerly: Chiron) related to certain aspects of the production of influenza viruses in cell culture.
The patent was revoked during oral proceedings. An appeal is currently pending. Should the outcome of the appeal be such that the patent is fully re-instated,

this may adversely affect the development and the commercialization by Crucell or its licensee of a cell based flu vaccine.

flosz 27 april 2010 15:25

crucell.com/annual_report_2009/pdfs/m...

.......

2007
In 2005 we lodged opposition against a European patent held by Chiron related to certain aspects of the production of influenza viruses in cell culture; the opposition is still pending.
hugin.info/132631/R/1219439/255908.pdf

2008
In 2005, we filed opposition against a European
patent held by Novartis Vaccines and Diagnostics
(formerly: Chiron) related to certain aspects of the production of influenza viruses in cell culture. The patent was revoked during oral proceedings.
www.crucell.com/annual_report_2008/do...
www.iex.nl/forum/topic.asp?forum=228&...

[verwijderd] 27 april 2010 16:36

quote:
flosz schreef:
crucell.com/annual_report_2009/pdfs/m...

.......

2007
In 2005 we lodged opposition against a European patent held by Chiron related to certain aspects of the production of influenza viruses in cell culture; the opposition is still pending.
hugin.info/132631/R/1219439/255908.pdf

2008
In 2005, we filed opposition against a European
patent held by Novartis Vaccines and Diagnostics
(formerly: Chiron) related to certain aspects of the production of influenza viruses in cell culture. The patent was revoked during oral proceedings.

Beste flosz,

Dank je voor het overzicht.
Geeft in ieder geval weer dat (pas?) nu in het rapport een directe link naar "affect the development and the commercialization" is toegevoegd.

Vandaar de eerder genoemde "mogelijke reden"; ik kan begrijpen dat Sanofi dit als "drog reden" naar Crucell hanteert, mede omdat de licentie afdrachten naar Chiron/ Novartis onbekend zijn, ten favoure van de eigen "egg solution" waarbij eventuele licentie kosten wel bekend zijn.

[verwijderd] 28 april 2010 09:27

L'Oreal says in no hurry to sell Sanofi stake

Reuters, Tuesday April 27 2010
* L'Oreal says Sanofi stake is financial, not operational

* Chairman says group keen to make an acquisition
PARIS, April 27 (Reuters) - French cosmetics giant L'Oreal on Tuesday said it was in no hurry to sell its 8.6 percent stake in pharmaceuticals group Sanofi-Aventis, which it described as a financial investment.

At current prices, the holding would be worth about 6.13 billion euros, a cash pile L'Oreal could use to finance a major acquisition.
"We are in no hurry to ($227 million) get out (of Sanofi)," L'Oreal Chairman Lindsay Owen-Jones told shareholders at the group's annual shareholder meeting.

However, he added that the holding was as a "reserve and a financial more than an operational investment."

Asked about the group's total available funds totalling some 10 billion euros, Owen-Jones said making an acquisitions remained a priority but there were few attractive opportunities currently.
On the other issue of advertising expenditure, Owen-Jones said he expected them to remain stable in 2010 after having reached 30.8 percent of sales during the downturn.

By 1344 GMT, L'Oreal shares were down 1.46 percent at 81.95 euros.
(Reporting by Pascale Denis; Writing by Astrid Wendlandt; Editing by Erica Billingham)

www.guardian.co.uk/business/feedartic...

DRW

[verwijderd] 29 april 2010 12:19

UPDATE: Sanofi's Quarterly Profit Up, Keeps Targets, Eyes Buys
Last update: 4/29/2010 3:40:01 AM

By Mimosa Spencer
Of DOW JONES NEWSWIRES
PARIS (Dow Jones)--French drugs giant Sanofi-Aventis (SAN.FR, SNY) Thursday kept its financial targets for the year and said the landscape is ripe for fresh acquisitions as it reported an 8.2% rise in first-quarter net profit, lifted by sales of its pandemic flu vaccine and key diabetes medicine Lantus.

"We're still shopping ... there is actually a positive environment," Sanofi Chief Executive Chris Viehbacher told a conference call on the results.

Net profit for the three months ended March 31 was EUR1.71 billion compared to EUR1.58 billion a year ago. Sanofi's revenue rose 3.9%, to EUR7.39 billion, just shy of analyst estimates for EUR7.44 billion, according to a Dow Jones Newswires poll of 9 analysts.

Fast sales growth from Lantus helped offset a drop in revenues from generic competition to its cancer drug Eloxatin.

Court rulings in the U.S. that will halt sales of copycat Eloxatin in June will not likely boost Sanofi's sales of the drug until early 2011, the company said.

A H1N1 flu vaccines added EUR413 million to sales, mostly from Latin America. Sanofi doesn't expect to book further orders for the pandemic flu vaccine unless there are changes in the pandemic's progression, Viehbacher said Thursday.

The company's seasonal flu vaccine will contain one of the A H1N1 strains, unless the pandemic suddenly strengthens.

Analysts highlighted margins as a strong point of Sanofi's first quarter report. Cost management was impressive, despite patent expirations on some important drugs such as Eloxatin, heart medicine Plavix and allergy medicine Allegra, said Gbola Amusa, an analyst with UBS. He added the company appears to be "ahead of the game" in managing costs of goods sold, a challenge for pharmaceutical companies losing patents on important drugs. He rates Sanofi neutral with a EUR59.50 target price.

Sanofi over the first-quarter continued to bolster its alternative sources of growth to blockbuster drugs facing patent expirations. Blockbuster is an industry term for drugs generating over $1 billion in annual sales.

In the past year, Sanofi Chief Executive Chris Viehbacher has built the company's acquisition strategy around vaccines, generics and over-the-counter portfolios, with a specific focus on emerging markets and on diabetes.

The company made EUR6.6 billion-worth of acquisitions last year, a pace it plans to maintain, Viehbacher repeated Thursday.

Sanofi confirmed its full-year target. The company expects to record growth of "business" earnings per share at constant rates of 2%-5% this year, excluding the effect of potential generic competition to its blood thinner Lovenox.

Business profit is the company's measure of net income attributable to equity holders excluding items such as amortization of intangible assets, impacts from acquisitions, restructuring costs and tax effects.

Pharmaceutical companies have shown resilience over the economic downturn, with vaccine makers getting an extra lift from government-sponsored A1H1 flu vaccination campaigns. U.K.-based rival GlaxoSmithKline PLC (GSK) Wednesday beat expectations with its first quarter earnings. At 0700 GMT, Sanofi shares traded up 0.8% or EUR0.42 at EUR52.30 in a lower Paris market. The stock has gained 20% in value over the past 12 months.

Company Web site: www.sanofi-aventis.com By Mimosa Spencer, Dow Jones Newswires; +33 1 40 17 17 73; mimosa.spencer@dowjones.com (END)

Dow Jones NewswiresApril 29, 2010 03:40 ET (07:40 GMT)

DRW

[verwijderd] 3 mei 2010 12:18

Glenmark Agrees To Give Drug License To Sanofi-Aventis
Last update: 5/2/2010 11:19:49 PM

BANGALORE (Dow Jones)--India's Glenmark Pharmaceuticals Ltd. (532296.BY) Monday said it has agreed to grant France's Sanofi-Aventis S.A. (SNY) a license to develop and commercialize new drugs to treat chronic pain.

Glenmark will receive an upfront payment of $20 million, as well as development, regulatory and commercial milestone payments, the Indian drug maker said in a statement. These payments could reach a total of $325 million.

Glenmark will also be eligible to receive tiered double-digit royalties on sales of products commercialized under the license, the statement added.

-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com
(END)

Dow Jones NewswiresMay 02, 2010 23:12 ET (03:12 GMT)

DRW

aossa 17 mei 2010 14:18

General meeting 17/05/2010

en.sanofi-aventis.com/investors/event...

en.sanofi-aventis.com/binaries/201004...

harvester 17 mei 2010 23:22

quote:
aossa schreef:
General meeting 17/05/2010

en.sanofi-aventis.com/investors/event...

en.sanofi-aventis.com/binaries/201004...

Allemaal niet zo bijzonder.
Erg veel goodwill ed. op de balans. Als daar op afgeschreven moet worden door generic competition of door tegenvallende omzet/winst bijdragen (shanta) dan zakt het Sanofi vermogen behoorlijk.
Voor Shanta was goodwill EUR 250 miljoen.

[verwijderd] 21 mei 2010 13:02

Total Lowers Its Voting Rights Level To 9.78% In Sanofi-Aventis
Last update: 5/21/2010 6:18:02 AM

PARIS (Dow Jones)--Oil company Total SA (TOT) has reduced the level of its voting rights in French drugmaker Sanofi-Aventis SA (SNY) below the 10% threshold, according to a filing with stock market regulator Autorite des Marches Financieres released Friday.

This results from the transfer of Sanofi-Aventis shares to broker-sponsored holdings and the sale of shares in the market.

Total currently holds 9.78% voting rights and 5.88% shares in the pharmaceutical company.

-By Elena Berton, Dow Jones Newswires; +33 1 4017 1765; elena.berton@dowjones.com (END)

Dow Jones NewswiresMay 21, 2010 06:18 ET (10:18 GMT

harvester 24 mei 2010 23:35

UNICEF yanks Sanofi vax, calls in Crucell 19 May 2010 - article via investorvillage posted there by flosz.

Sanofi's loss is Crucell's gain. As pediatricians in Kathmandu work to calm parents unable to have their infants vaccinated against five diseases, Sanofi Aventis' Indian unit Shantha is scrambling to find the cause of a white sediment in some vials of its Shan5 vaccine. Meanwhile, Crucell is ramping up to fill the gap.
Shan5 is a prophylactic for diphtheria, pertussis, tetanus, Haemophilus influenza B, and hepatitis B. Reports of the sediment began in March, followed by a World Health Organization suspension of the vaccine for use in a distribution program. Shan5 represents a $340 million contract that the Indian drugmaker won last fall.
Some Nepalese parents have decided to cough up $14 for another pentavalent vaccine available at some hospitals, despite assurances that shipments are on their way and the free-vaccine program will resume in a matter of weeks.
The white sediment is reportedly difficult to disperse, even when the vial is shaken. It's not likely a contaminant because the vaccine passed QA tests prior to shipment, the company said in March. A more likely scenario is that part of the vaccine contents condensed in transit, perhaps due to improper storage or shipping conditions.
UNICEF and the WHO in late April recommended the recall and destruction of vaccine still in stock--about 24 million doses--due to the mysterious sediment. The move has affected vaccination programs in seven countries, says the WHO. No safety issues or adverse events have been reported.
The WHO and UNICEF want Shantha to find out what went wrong and to develop a corrective plan before the end of June. Shantha will otherwise be disqualified as a supplier. The company says it has put together a team of specialists to find the cause and resume shipments before the end of the year.
Meanwhile, Dutch biotech Crucell has won a $110 million UNICEF order for its pentavalent Quinvaxem, giving the company a much-needed market boost against Shantha and Panacea Biotech, according to Reuters. The news agency cites a Crucell spokeswoman who said that the Quinvaxem order from UNICEF was due to supply problems experienced by "another company."

www.fiercepharmamanufacturing.com/sto...

harvester 24 mei 2010 23:45

Vaccine arrival 26 May 750,000 >Nepal
Aannemende quinvaxem dus deel van de (shanta)replacement order in mei omzet.
2010-05-23
Himalayan News Service
KATHMANDU: Nepal is all set to receive the first consignment of the Pentavalent vaccine on May 26, easing the acute shortage the country is reeling under, the United Nation’s Children Fund (UNICEF) said. Dr Sudhir Khanal, programme officer at UNICEF, said that the UNICEF Supply Division in Copenhagen had already dispatched a consignment of 750,000 doses of the drug on May 17. The vaccine is used to immunise children under one years of age against Tetanus, Diphtheria, Pertussis, Hepatitis B and Haemophilus Influenza. On April 12, Nepal received the first consignment of the vaccine that was procured from the global company, Crucell Berna, after World Health Organisation (WHO) recommended the disposal of previously-used vaccines manufactured by the Indian company, Shanta Biotechs. A total of 131,600 vials were received under the first consignment. The UNICEF is witnessing problems to get required quantities of the vaccine as WHO has pre-qualified only few companies for global supply. Krishna Bahadur Chand, chief of Immunisation Programme at Child Health Division at the Department of Health Services, said they would dispatch the vaccine within two days once they receive them. — HNS
www.thehimalayantimes.com/fullNews.ph...

aossa 26 mei 2010 15:41

India plans manufacturing plant subsidy for mid-sized pharmas

25-May-2010
The Indian Government plans to help medium sized pharmaceutical firms meet World Health Organisation (WHO) manufacturing plant standards with a new subsidy scheme.

Ashok Kumar, secretary of the Government Department of Pharmaceuticals told Livemint that: “We are currently in the process of making the proposal [which when finalised will be sent] to the Planning Commission for clearance.”

Kumar added that because most medium-scale drugmakers in India already comply with Schedule “M” of the country’s Drug and Cosmetics Act “it will not be very hard to get WHO GMP [good manufacturing practices] certification.”

The new scheme, outlined in a post on the Department of Pharmaceuticals’ website, would be similar to an existing subsidy programme available to small-scale pharma firms.

That programme offers such pharmaceutical producers a 15 per cent capital subsidy for manufacturing facility investment and equipment projects worth up to a maximum value of INR1m.

785 Posts, Pagina: « 1 2 3 4 5 6 ... 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	918,42	+16,74	+1,86%	16:43
AMX	923,14	+4,12	+0,45%	16:43
ASCX	1.248,31	+4,42	+0,36%	16:28
BEL 20	3.899,25	-20,21	-0,52%	16:43
Germany40^	18.558,60	+152,96	+0,83%	16:43
US30^	38.635,40	-57,30	-0,15%	16:43
US500^	5.314,48	+25,22	+0,48%	16:43
Nasd100^	18.877,40	+228,20	+1,22%	16:42
Japan225^	38.763,60	+339,50	+0,88%	16:40
WTI	73,56	+0,24	+0,33%	16:43
Brent	77,83	+0,36	+0,46%	16:42
EUR/USD	1,0876	-0,0003	-0,03%	16:43
BTC/USD	70.963,92	+378,70	+0,54%	16:43
Gold spot	2.349,22	+22,32	+0,96%	16:43